Medical - Devices
Compare Stocks
5 / 10Stock Comparison
INSP vs IRTC vs ITGR vs NVCR vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
INSP vs IRTC vs ITGR vs NVCR vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $1.31B | $4.10B | $3.03B | $1.92B | $16.97B |
| Revenue (TTM) | $915M | $788M | $1.85B | $674M | $4.13B |
| Net Income (TTM) | $131M | $-28M | $142M | $-173M | $544M |
| Gross Margin | 85.8% | 71.0% | 23.3% | 75.2% | 52.8% |
| Operating Margin | 5.6% | -3.3% | 10.4% | -27.2% | 17.5% |
| Forward P/E | 24.5x | — | 13.5x | — | 17.2x |
| Total Debt | $32M | $731M | $1.40B | $290M | $2.63B |
| Cash & Equiv. | $105M | $236M | $17M | $103M | $1.96B |
INSP vs IRTC vs ITGR vs NVCR vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Inspire Medical Sys… (INSP) | 100 | 55.9 | -44.1% |
| iRhythm Technologie… (IRTC) | 100 | 100.5 | +0.5% |
| Integer Holdings Co… (ITGR) | 100 | 111.0 | +11.0% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INSP vs IRTC vs ITGR vs NVCR vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INSP has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 13.6%, EPS growth 179.4%, 3Y rev CAGR 30.8%
- 14.3% margin vs NVCR's -25.7%
- 15.2% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4%
IRTC ranks third and is worth considering specifically for long-term compounding.
- 379.3% 10Y total return vs ITGR's 165.1%
- 26.2% revenue growth vs HOLX's 1.7%
ITGR is the clearest fit if your priority is value.
- Lower P/E (13.5x vs 17.2x)
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
HOLX is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- Beta 0.41 vs NVCR's 2.20, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 26.2% revenue growth vs HOLX's 1.7% | |
| Value | Lower P/E (13.5x vs 17.2x) | |
| Quality / Margins | 14.3% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.41 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +37.1% vs INSP's -70.9% | |
| Efficiency (ROA) | 15.2% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4% |
INSP vs IRTC vs ITGR vs NVCR vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INSP vs IRTC vs ITGR vs NVCR vs HOLX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INSP leads in 2 of 6 categories
HOLX leads 1 • IRTC leads 0 • ITGR leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — INSP and HOLX each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 6.1x NVCR's $674M. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, IRTC holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $915M | $788M | $1.8B | $674M | $4.1B |
| EBITDAEarnings before interest/tax | $62M | -$6M | $328M | -$165M | $974M |
| Net IncomeAfter-tax profit | $131M | -$28M | $142M | -$173M | $544M |
| Free Cash FlowCash after capex | $97M | $19M | $168M | -$48M | $1000M |
| Gross MarginGross profit ÷ Revenue | +85.8% | +71.0% | +23.3% | +75.2% | +52.8% |
| Operating MarginEBIT ÷ Revenue | +5.6% | -3.3% | +10.4% | -27.2% | +17.5% |
| Net MarginNet income ÷ Revenue | +14.3% | -3.5% | +7.7% | -25.7% | +13.2% |
| FCF MarginFCF ÷ Revenue | +10.6% | +2.4% | +9.1% | -7.1% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.6% | +25.7% | +0.8% | +12.3% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -5.0% | +55.7% | +172.7% | -100.0% | -9.2% |
Valuation Metrics
INSP leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 9.3x trailing earnings, INSP trades at a 69% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, ITGR's 13.1x EV/EBITDA is more attractive than INSP's 19.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.3B | $4.1B | $3.0B | $1.9B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $4.6B | $4.4B | $2.1B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | 9.32x | -89.83x | 30.42x | -13.80x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.46x | — | 13.55x | — | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.91x | — | — |
| EV / EBITDAEnterprise value multiple | 19.11x | — | 13.15x | — | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 1.44x | 5.49x | 1.64x | 2.92x | 4.14x |
| Price / BookPrice ÷ Book value/share | 1.74x | 26.16x | 1.79x | 5.51x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 16.73x | 118.84x | 28.78x | — | 18.44x |
Profitability & Efficiency
INSP leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-51 for NVCR. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs NVCR's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +18.0% | -20.6% | +8.2% | -50.8% | +11.0% |
| ROA (TTM)Return on assets | +15.2% | -2.8% | +4.2% | -16.5% | +6.1% |
| ROICReturn on invested capital | +6.0% | -5.2% | +5.4% | -16.4% | +9.4% |
| ROCEReturn on capital employed | +6.7% | -4.4% | +6.9% | -28.9% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 5 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.04x | 4.79x | 0.80x | 0.85x | 0.52x |
| Net DebtTotal debt minus cash | -$73M | $495M | $1.4B | $187M | $667M |
| Cash & Equiv.Liquid assets | $105M | $236M | $17M | $103M | $2.0B |
| Total DebtShort + long-term debt | $32M | $731M | $1.4B | $290M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 418.58x | -1.48x | 5.07x | -96.80x | 8.00x |
Total Returns (Dividends Reinvested)
Evenly matched — IRTC and ITGR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRTC five years ago would be worth $15,609 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs INSP's -70.9%. The 3-year compound annual growth rate (CAGR) favors ITGR at 2.9% vs INSP's -45.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -50.6% | -28.7% | +14.5% | +28.3% | +1.9% |
| 1-Year ReturnPast 12 months | -70.9% | -8.3% | -26.1% | +1.1% | +37.1% |
| 3-Year ReturnCumulative with dividends | -83.9% | -2.1% | +8.8% | -75.7% | -8.5% |
| 5-Year ReturnCumulative with dividends | -76.6% | +56.1% | -7.5% | -91.3% | +15.8% |
| 10-Year ReturnCumulative with dividends | +82.4% | +379.3% | +165.1% | +30.3% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -45.6% | -0.7% | +2.9% | -37.6% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs INSP's 27.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 0.93x | 0.72x | 2.20x | 0.41x |
| 52-Week HighHighest price in past year | $163.35 | $212.00 | $123.78 | $20.06 | $76.04 |
| 52-Week LowLowest price in past year | $44.41 | $112.31 | $62.00 | $9.82 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +27.9% | +58.9% | +71.0% | +83.9% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 31.6 | 44.1 | 50.9 | 69.8 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 524K | 628K | 1.5M | 10.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INSP as "Hold", IRTC as "Buy", ITGR as "Buy", NVCR as "Buy", HOLX as "Hold". Consensus price targets imply 100.4% upside for INSP (target: $91) vs 3.9% for HOLX (target: $79).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $91.33 | $193.67 | $98.00 | $33.50 | $79.00 |
| # AnalystsCovering analysts | 27 | 19 | 14 | 15 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +13.3% | 0.0% | +1.7% | 0.0% | +4.4% |
INSP leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). HOLX leads in 1 (Risk & Volatility). 2 tied.
INSP vs IRTC vs ITGR vs NVCR vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INSP or IRTC or ITGR or NVCR or HOLX a better buy right now?
For growth investors, iRhythm Technologies, Inc.
(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 9. 3x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate iRhythm Technologies, Inc. (IRTC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INSP or IRTC or ITGR or NVCR or HOLX?
On trailing P/E, Inspire Medical Systems, Inc.
(INSP) is the cheapest at 9. 3x versus Hologic, Inc. at 30. 5x. On forward P/E, Integer Holdings Corporation is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — INSP or IRTC or ITGR or NVCR or HOLX?
Over the past 5 years, iRhythm Technologies, Inc.
(IRTC) delivered a total return of +56. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: IRTC returned +379. 3% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INSP or IRTC or ITGR or NVCR or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — INSP or IRTC or ITGR or NVCR or HOLX?
By revenue growth (latest reported year), iRhythm Technologies, Inc.
(IRTC) is pulling ahead at 26. 2% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, INSP leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INSP or IRTC or ITGR or NVCR or HOLX?
Inspire Medical Systems, Inc.
(INSP) is the more profitable company, earning 15. 9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INSP or IRTC or ITGR or NVCR or HOLX more undervalued right now?
On forward earnings alone, Integer Holdings Corporation (ITGR) trades at 13.
5x forward P/E versus 24. 5x for Inspire Medical Systems, Inc. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INSP: 100. 4% to $91. 33.
08Which pays a better dividend — INSP or IRTC or ITGR or NVCR or HOLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INSP or IRTC or ITGR or NVCR or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INSP and IRTC and ITGR and NVCR and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INSP is a small-cap deep-value stock; IRTC is a small-cap high-growth stock; ITGR is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.